Director’s Report to the National Advisory Council on Drug Abuse

September 10, 2020

Nora D. Volkow, M.D., Director

NIH National Institute on Drug Abuse

@NIDAnews
## NIDA Budget

<table>
<thead>
<tr>
<th></th>
<th>FY 2019 Actuals ($k)</th>
<th>FY 2020 Enacted ($k)</th>
<th>FY 2021 PB ($k)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Base</strong></td>
<td>$1,150,367</td>
<td>$1,191,403</td>
<td>$1,165,449</td>
</tr>
<tr>
<td><strong>HEAL</strong></td>
<td>$470,967*</td>
<td>$266,321</td>
<td>$266,321</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$1,621,334*</td>
<td>$1,457,724</td>
<td>$1,431,770</td>
</tr>
</tbody>
</table>

*Reflects total HEAL funding obligated in FY 19, regardless of source. Includes 1-year funds provided in FY 19 and balance of 2-year funds provided in FY 18.
TRANS-NIH COVID-19 EFFORTS

In response to COVID-19, NIH has multi-IC collaborative efforts to address interdisciplinary challenges associated with the pandemic.

These efforts directly support the NIH’s Strategic Priorities outlined in its Strategic Plan for COVID-19 Research:

- Improve Fundamental Knowledge
- Advance Research to Improve Detection
- Support Research to Advance Treatment
- Accelerate Research to Improve Prevention
- Prevent and Redress Poor COVID-19 Outcomes
Adolescent Brain Cognitive Development (ABCD) Study

COVID-19 Adjustments

- Resumed 2-year follow-up visits (either virtually or hybrid)
  - In-person - brain imaging, select neurocog assessments and sensitive questionnaires
- No biospecimen collection
- 3-year follow-ups continuing virtually

COVID-19 Data Collection

- Monthly COVID-19 questionnaires beginning May
  - Funded by NSF, NIDA, NIMH, OBSSR, Children and Screens
  - Characterize community- and regional-level impacts of COVID-19 by geocoding measures of incidence, spatial distancing, changes in (un)employment, and timing of state and/or local policies on mitigation practices
  - Funded by NIH COVID-19 Social, Behavioral, and Economic Impacts Group

ABCD Data Release 3.0 Fall 2020 – 6-month and 1-year follow-up data for the full cohort; interim 18-, 24-, 30-month data

98.8 Percent Retained

PUBLICATIONS USING ABCD DATA

2018 2019 2020

2 14 19

2 7 14

22 22 22

ABCD investigators
Non-ABCD investigators
Effects of Lead Exposure on Cognition and Brain Structure Modulated by Socioeconomics (ABCD 9712; 9-10 years old)

Children of Parents who were in *Raising Healthy Children Intervention* in Grades 1-6 (n=72) Compared to Controls (n=110) through ages 1-18

- Academic skills
- Cognitive skills

- Ever tried any drug
- Ever drank alcohol

- Oppositional defiance problems
- Conduct problems
- Affective problems
- ADHD
- Externalizing disorders
- Internalizing disorders

*Hill KG et al., JAMA Pediatr. 2020*
Significant Increases in Teens VAPING

**NICOTINE**

- **Daily Nicotine Vaping**
  - 8th graders: 1.9%
  - 10th graders: 6.9%
  - 12th graders: 11.7%

- **Nicotine Vaping**
  - Past month use:
    - 2017: 9.6%
    - 2018: 19.9%
    - 2019: 25.5%

**THC**

- **THC Vaping**
  - Past month use:
    - 2017: 3.9%
    - 2018: 12.6%
    - 2019: 14%

- **Daily THC Vaping**
  - Measured for the first time in 2019
  - 8th graders: 0.8%
  - 10th graders: 3.0%
  - 12th graders: 3.5%

*2018 – 2019 increase is the second largest one-year jump ever tracked for any substance in the 45-year survey history (nicotine vaping was the largest from 2017 – 2018)*

**SOURCE:** University of Michigan, 2019

*Monitoring the Future Study*

---


2019 Past Month Nicotine Vaping Equates to:
- 1 in 4 – 12th Graders
- 1 in 5 – 10th Graders
- 1 in 10 – 8th Graders
Vaping of Marijuana and Nicotine rose sharply in the past three years among college-age (19-22 years old) individuals.

**Marijuana Vaping**

- 2017: College 5.2, Non-College 7.8
- 2019: College 14, Non-College 17

**Nicotine Vaping**

- 2017: College 6.1, Non-College 7.9
- 2019: College 22, Non-College 18

*Source: Monitoring the Future 2019 Survey on College Age Adults.*
Overdose Deaths in 2019 Increased by 4.6%

Number of Deaths

- Fentanyl, 37,137
- Prescription opioids, 14,347
- Heroin, 14,278
- Methamphetamine, 16,539
- Cocaine, 16,196

Source: CDC NVSS Vital Statistics Rapid Release Provisional Drug Overdose Death Counts
Intersection Between Opioid Crisis and COVID-19
Millennium Health Signals Report™ COVID-19 Special Edition:
Significant Changes in Drug Use During the Pandemic Volume 2.1 Published July 2020

Total Study Population Change in Unadjusted Positivity Rate for Cocaine, Fentanyl, Heroin and Methamphetamine
Overdoses Grew Dramatically During COVID Pandemic

Overdoses increased up to 42% per month during the pandemic, as compared to the same months in 2019.

Note: Percent growth references the 1,201 agencies reporting to ODMAP by January

Source: ODMAP

ALYSSA FOWERS/ THE WASHINGTON POST
HEALing Communities Study

• Has the rate of overdoses changed?
• Impact on treatment initiation and retention
• Impact on drug access in the community
• Challenges to providers and first responders
• Challenges to those with SUD

Justice Community Opioid Innovation Network

• Compiled >120 guidelines/resources for justice systems responding to COVID-19
• Advisory group to provide real-time information to NIDA COVID-19 impact in justice settings

18 States + PR
88 communities
>25,000 justice-involved persons
Overdose Encounters in HEALing Communities States

**Kentucky HCS Opioid Overdose-related Encounters: 2018-2020, N=16 Communities**

*Year of Encounter* 2018 2019 2020

**Emergency Medical Services Runs**

Data Sources: Kentucky Board of Emergency Medical Services data and Syndromic surveillance of emergency department visits

**Emergency Department Visits**

Solid lines represent LOESS Regression of Opioid Overdose Encounters. Points represent raw counts of records.

**Massachusetts HCS Opioid Overdose-related Encounters: 2019-2020, N=16 Communities**

*Year of Encounter* 2019 2020

**Emergency Medical Services Runs**

Data Sources: MA Department of Public Health; MA Ambulance Trip Information System and Syndromic Surveillance data

**Emergency Department Visits**

Solid lines represent LOESS Regression of Opioid Overdose Encounters. Points represent raw counts of records.

**New York HCS Opioid Overdose-related Encounters: 2018-2020, N=16 Communities**

*Year of Encounter* 2018 2019 2020

**EMS Administration of Naloxone**

Data Sources: New York State Bureau of Emergency Medical Services and Trauma Systems and Syndromic Surveillance of emergency department visits

**Emergency Department Visits**

Solid lines represent LOESS Regression of Opioid Overdose Encounters. Points represent raw counts of records.

**Ohio HCS Opioid Overdose-related Encounters: 2018-2020, N=19 Communities**

*Year of Encounter* 2018 2019 2020

**Emergency Medical Services Runs**

Data Sources: Ohio syndromic surveillance of emergency department visits

**Emergency Department Visits**

Solid lines represent LOESS Regression of Opioid Overdose Encounters. Points represent raw counts of records.
COVID Policy Changes for Prescribing Medications for OUD

Methadone (II)

• **Prior to COVID:**
  • only federally approved OTPs
  • in person for daily dosing

• **Under COVID, SAMHSA allowed:**
  • 3/16/2020: 28 day take home
  • 3/20/2020; for those under quarantine: surrogate take home or door-step delivery
  • Still requires in person visit for first dose

Buprenorphine (III)

• **Prior to COVID:**
  • Prescribed through pharmacies in outpatient settings
  • DATA 2000, limited to Clinicians with Bup waivers that required additional training and federal registration
  • Limited number of patients to treat.
  • In person evaluation for initial dose

• **Under COVID, DEA allowed:**
  • 3/17/2020: Buprenorphine initiation through telehealth (including phone) without in-person visit
  • Follow up can be via phone
Additional Opportunities in SUD Treatment Under COVID

- Increased use of telemedicine and its reimbursement
  - Expanded access to Treatment of Co-morbid conditions
  - Expanded access to Behavioral Treatments
  - Establishment of Mental Health hot lines
  - Deployment of virtual support meetings and coaches

- Changes in Justice settings
  - Release of non-violent offenders with SUD from jails/prisons
  - Expanded use of telemedicine including for MOUD
  - Expanded opportunities for education via web-based program
U.S. Overdose Deaths Involving Cocaine, by Race

- White (NH), 4.6
- Black (NH), 9.0
- Asian or PI (NH), 0.6
- Hispanic, 3.0
- AI/AN (NH), 3.2
- U.S., 4.5

Source: CDC WONDER

U.S. Overdose Deaths Involving Methamphetamine, by Race

- White (NH), 5.0
- Black (NH), 2.2
- Asian or PI (NH), 1.3
- Hispanic, 2.5
- AI/AN (NH), 10.8
- U.S., 3.9

ICD-10 codes: T40.5, cocaine

This category is dominated by methamphetamine related overdoses.

Source: CDC WONDER
<table>
<thead>
<tr>
<th>Stimulant (Cocaine and Methamphetamine) Use Disorder Medication Pipeline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Early Preclinical</strong> (T2L: &gt;12 yrs)</td>
</tr>
<tr>
<td>SBI-0069330 or SBI-0801315 * + mGluR2 PAM</td>
</tr>
<tr>
<td>NOP/Kappa/Mu ligands *</td>
</tr>
<tr>
<td>PTPRD ligands * +</td>
</tr>
<tr>
<td>Peptidic KOR agonists *</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Black – NME  Red – New Indication  Blue – Biologic  Green – Gene Therapy  * cocaine  + meth  * + cocaine or meth
We are here

Winter 2020
Present framework to NACDA

Spring 2020
Draft outline

Summer 2020
Incorporate stakeholder feedback

Fall 2021
Begin drafting; RFI Report to NACDA

Winter 2021
NACDA feedback; Finalize draft

Spring 2021
Launch and promote NIDA Strategic Plan!

Winter 2021
NACDA approval; final NIH approval

Spring 2021
Draft to NACDA

Summer 2020
Present outline to NACDA; Publish RFI

Fall 2021
NACDA feedback;
Finalize draft

Senior leadership approval;
Finalize web and promotional material

Senior leadership approval
Consult with Program staff
Program staff review

We are here
NIDA Initiative to Promote Racial Equity

Gaya Dowling, HQ/DER
Emily Einstein, HQ/OSPC

NIDA Workplace
Joellen Austin, HQ
Marisela Marsalis, IRP

NIDA-wide Subgroup
Redonna Chandler, HQ/OD
Lorenzo Leggio, IRP

HQ Subgroup
Mary Kautz, DNB
Ericka Wells, DER

IRP Subgroup
Brenda Curtis, IRP (TT)
Leslie Premo, IRP (OSD)

Scientific Research Workforce
Albert Avila, HQ/ODHD
Michelle Jobes, IRP

IRP Subgroup
Brenda Curtis, IRP (TT)
Leslie Premo, IRP (OSD)

Research Gaps and Opportunities
Will Akin, HQ/DTMC
Carlos Blanco, HQ/DESPR

NIDA-wide Subgroup
Redonna Chandler, HQ/OD
Lorenzo Leggio, IRP

• Stacy Gardner, HQ/OM
• Dharm Rathore, HQ/DER
• Carrie Wertheim, IRP
• Da-Yu Wu, HQ/DNB

• Tara Garwood, HQ/OSPC
• Chloe Jordan, HQ/DER
• Guifang Lao, DTMC
• Brian O’Laughlin, HQ/OM
• Julia Zur, HQ/DESPR

• Flavia Barbano, IRP
• Albert Burgess-Hull, IRP
• David Reiner, IRP
• Javier Rubio, IRP
• Mitchele Williams, IRP

• Christie Brannock, IRP
• Alice Delaney, IRP
• Katrina Foster, HQ/DTMC
• Chase Francis, IRP
• Julie Frost, HQ/OSPC
• Marsha Lopez, HQ/DESPR
• Jonathan Pollock, HQ/DNB
• Katherine Savell, IRP
• Ayesha Sengupta, IRP
• Adrienne Snyder, IRP
• Rina Valintino, HQ/DNB
• Kevin Walton, HQ/DTMC
Science Behind Addiction LIVE Video series

Addressing Race, Equity and Inclusion

Emergency Care and SUD During COVID-19
Jack B. Stein, Ph.D.
National Association of State Alcohol and Drug Abuse Directors (NASADAD)
Harwood/Anderson Service Award

This award is given to a member or non-member of NASADAD in recognition of their distinguished service in the field of addiction research, training, and evaluation.
NIDA Headquarters
On the Move...

3 White Flint North
11601 Landsdown Street Bethesda MD

- NIDA’s OA moved November 18, 2019
- The rest of NIDA HQ moved July 21, 2020